Liquidia Technologies Inc (LQDA) - Net Assets

Latest as of September 2025: $22.05 Million USD

Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has net assets worth $22.05 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($275.98 Million) and total liabilities ($253.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Liquidia Technologies Inc (LQDA) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $22.05 Million
% of Total Assets 7.99%
Annual Growth Rate N/A
5-Year Change 8.71%
10-Year Change N/A
Growth Volatility 52.9

Liquidia Technologies Inc - Net Assets Trend (2016–2024)

This chart illustrates how Liquidia Technologies Inc's net assets have evolved over time, based on quarterly financial data. Also explore LQDA total assets for the complete picture of this company's asset base.

Annual Net Assets for Liquidia Technologies Inc (2016–2024)

The table below shows the annual net assets of Liquidia Technologies Inc from 2016 to 2024. For live valuation and market cap data, see Liquidia Technologies Inc (LQDA) market capitalisation.

Year Net Assets Change
2024-12-31 $77.28 Million +63.40%
2023-12-31 $47.29 Million -47.70%
2022-12-31 $90.42 Million +38.55%
2021-12-31 $65.27 Million -8.19%
2020-12-31 $71.09 Million +103.41%
2019-12-31 $34.95 Million +87.01%
2018-12-31 $18.69 Million +155.47%
2017-12-31 $-33.69 Million -84.66%
2016-12-31 $-18.25 Million --

Equity Component Analysis

This analysis shows how different components contribute to Liquidia Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 47523292900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $85.00K 0.11%
Other Components $636.68 Million 823.92%
Total Equity $77.28 Million 100.00%

Liquidia Technologies Inc Competitors by Market Cap

The table below lists competitors of Liquidia Technologies Inc ranked by their market capitalization.

Company Market Cap
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
$3.32 Billion
Amedisys Inc
NASDAQ:AMED
$3.32 Billion
Autel Intelligent Technology Corp Ltd
SHG:688208
$3.32 Billion
China Petroleum Engineering Corp
SHG:600339
$3.33 Billion
Trigano S.A.
PA:TRI
$3.32 Billion
CI Financial Corp
TO:CIX
$3.32 Billion
WesBanco Inc
NASDAQ:WSBC
$3.32 Billion
Zhejiang Yongtai Technology Co Ltd
SHE:002326
$3.31 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Liquidia Technologies Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 47,293,000 to 77,275,000, a change of 29,982,000 (63.4%).
  • Net loss of 130,394,000 reduced equity.
  • New share issuances of 138,551,000 increased equity.
  • Other factors increased equity by 21,825,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-130.39 Million -168.74%
Share Issuances $138.55 Million +179.3%
Other Changes $21.82 Million +28.24%
Total Change $- 63.40%

Book Value vs Market Value Analysis

This analysis compares Liquidia Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 38.85x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2016-12-31 $-3.59 $38.14 x
2017-12-31 $-3.92 $38.14 x
2018-12-31 $2.61 $38.14 x
2019-12-31 $1.89 $38.14 x
2020-12-31 $2.10 $38.14 x
2021-12-31 $1.31 $38.14 x
2022-12-31 $1.48 $38.14 x
2023-12-31 $0.73 $38.14 x
2024-12-31 $0.98 $38.14 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Liquidia Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -168.74%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -931.65%
  • • Asset Turnover: 0.06x
  • • Equity Multiplier: 2.98x
  • Recent ROE (-168.74%) is below the historical average (-104.18%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 0.00% -120.56% 1.56x 0.00x $-14.11 Million
2017 0.00% -401.68% 0.49x 0.00x $-25.79 Million
2018 -284.34% -1962.92% 0.05x 2.64x $-55.00 Million
2019 -136.16% -589.48% 0.12x 1.97x $-51.08 Million
2020 -84.07% -8080.11% 0.01x 1.40x $-66.87 Million
2021 -52.98% -269.03% 0.14x 1.44x $-41.11 Million
2022 -45.36% -257.39% 0.12x 1.43x $-50.06 Million
2023 -165.99% -448.89% 0.15x 2.50x $-83.23 Million
2024 -168.74% -931.65% 0.06x 2.98x $-138.12 Million

Industry Comparison

This section compares Liquidia Technologies Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $248,191,134
  • Average return on equity (ROE) among peers: -119.98%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Liquidia Technologies Inc (LQDA) $22.05 Million 0.00% 11.52x $3.32 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-34.80 Million 0.00% 0.00x $118.88 Million
Abcellera Biologics Inc (ABCL) $1.15 Billion -12.70% 0.29x $1.07 Billion
Abeona Therapeutics Inc (ABEO) $134.04 Million -42.28% 0.30x $292.09 Million
Acumen Pharmaceuticals Inc (ABOS) $266.97 Million -19.62% 0.16x $171.87 Million
Abpro Holdings, Inc. (ABP) $-14.95 Million 0.00% 0.00x $448.19K
Absci Corp (ABSI) $274.41 Million -38.23% 0.17x $345.85 Million
Arbutus Biopharma Corp (ABUS) $169.44 Million -45.00% 0.21x $840.56 Million
ABVC Biopharma Inc (ABVC) $8.87 Million -144.74% 0.54x $26.41 Million
Abivax SA American Depositary Shares (ABVX) $7.19 Million -844.90% 9.51x $9.33 Billion
ACADIA Pharmaceuticals Inc (ACAD) $518.41 Million -52.35% 0.08x $3.74 Billion

About Liquidia Technologies Inc

NASDAQ:LQDA USA Biotechnology
Market Cap
$3.32 Billion
Market Cap Rank
#4636 Global
#1496 in USA
Share Price
$38.14
Change (1 day)
-2.73%
52-Week Range
$12.00 - $46.63
All Time High
$46.63
About

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more